Acadia Pharmaceuticals
ACAD
233 hedge funds and large institutions have $2.97B invested in Acadia Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 76 increasing their positions, 69 reducing their positions, and 28 closing their positions.
143% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $4.48M
29% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 28
20% more capital invested
Capital invested by funds: $2.48B → $2.97B (+$499M)
10% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 69
3% more funds holding
Funds holding: 227 → 233 (+6)
0.99% more ownership
Funds ownership: 96.01% → 97% (+0.99%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$87.1M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$23.3M |
| 3 |
Morgan Stanley
New York
|
+$22.3M |
| 4 |
D.E. Shaw & Co
New York
|
+$13M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$41M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$28.3M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$23.8M |
| 4 |
Man Group
London,
United Kingdom
|
-$18.2M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$11.2M |
ACAD Hedge Fund Activity: Q1 2023 in Review
233 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q1 2023, worth a combined $2.97B — up 20% from $2.48B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ACAD positions and 28 closed out — a net gain of 8 holders — while 76 added to existing stakes and 69 trimmed.
The largest buyer was RTW Investments, adding an estimated $87.1M. The largest seller was State Street, cutting an estimated $41M.
- 233 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q1 2023, up from 227 in Q4 2022.
- Funds reported $2.97B of Acadia Pharmaceuticals stock for Q1 2023, up 20% quarter-over-quarter.
- 36 funds opened new Acadia Pharmaceuticals positions in Q1 2023 and 28 closed out, a net change of +8 holders.
- The largest Acadia Pharmaceuticals buyer in Q1 2023 was RTW Investments, an estimated $87.1M added.
- The largest Acadia Pharmaceuticals seller in Q1 2023 was State Street, an estimated $41M sold.
Based on aggregated 13F filings for Q1 2023.